Generic drug combo may improve breast cancer outcomes

Aromatase inhibitors and bisphosphonates each appear to improve outcomes among postmenopausal women with breast cancer, according to two studies in The Lancet, and combination treatment with the two complementary drugs could be even more effective. One study found that postmenopausal women who took aromatase inhibitors have a 40% lower risk of dying within 10 years, and recurrence was 30% lower than in those treated with tamoxifen. In a separate study, bisphosphonates were linked to 18% lower mortality. The Washington Post (tiered subscription model) (7/27)